The in-vitro influence of urea concentration on thromboelastrography in patients with and without end stage renal disease.

[1]  T. Jenssen,et al.  Sex Differences in Age-Related Loss of Kidney Function , 2022, Journal of the American Society of Nephrology : JASN.

[2]  J. Fryc,et al.  Thrombolome and Its Emerging Role in Chronic Kidney Diseases , 2021, Toxins.

[3]  W. Kemp,et al.  Viscoelastic Tests as Point-of-Care Tests in the Assessment and Management of Bleeding and Thrombosis in Liver Disease , 2020, Seminars in Thrombosis and Hemostasis.

[4]  A. Stinghen,et al.  How do Uremic Toxins Affect the Endothelium? , 2020, Toxins.

[5]  H. Meng,et al.  Correlation between breath ammonia and blood urea nitrogen levels in chronic kidney disease and dialysis patients , 2020, Journal of breath research.

[6]  L. G. Vu,et al.  Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The Lancet.

[7]  S. Ito,et al.  Uremic toxins alter coagulation and fibrinolysis-related genes expression in human endothelial cells. , 2019, Thrombosis research.

[8]  James G. Chandler,et al.  Untangling Sex Dimorphisms in Coagulation: Initial Steps Towards Precision Medicine for Trauma Resuscitation. , 2019, Annals of surgery.

[9]  A. Sauaia,et al.  Not All in Your Head (and Neck): Stroke after Blunt Cerebrovascular Injury Is Associated with Systemic Hypercoagulability. , 2019, The journal of trauma and acute care surgery.

[10]  A. Schmidt,et al.  The Utility of Thromboelastography to Guide Blood Product Transfusion. , 2019, American journal of clinical pathology.

[11]  S. Nigam,et al.  Uraemic syndrome of chronic kidney disease: altered remote sensing and signalling , 2019, Nature Reviews Nephrology.

[12]  S. Burtey,et al.  Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease , 2018, Toxins.

[13]  J. Grotta,et al.  Thrombelastography Suggests Hypercoagulability in Patients with Renal Dysfunction and Intracerebral Hemorrhage. , 2018, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[14]  A. Sauaia,et al.  The hypercoagulability paradox of chronic kidney disease: The role of fibrinogen. , 2017, American journal of surgery.

[15]  P. Johansson,et al.  The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products – A systematic review and meta-analysis , 2017, Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine.

[16]  D. Warnock,et al.  The global burden of chronic kidney disease: estimates, variability and pitfalls , 2017, Nature Reviews Nephrology.

[17]  J. Hodson,et al.  Preoperative Thromboelastography as a Sensitive Tool Predicting Those at Risk of Developing Early Hepatic Artery Thrombosis After Adult Liver Transplantation , 2016, Transplantation.

[18]  F. Hobbs,et al.  Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis , 2016, PloS one.

[19]  M. Maciejewski,et al.  The Economic Burden of Chronic Kidney Disease and End-Stage Renal Disease. , 2016, Seminars in nephrology.

[20]  Moshe Shashar,et al.  Thrombosis in the Uremic Milieu—Emerging Role of “Thrombolome” , 2015, Seminars in dialysis.

[21]  L. McCullough,et al.  Sex differences in stroke: The contribution of coagulation , 2014, Experimental Neurology.

[22]  À. Argilés,et al.  Does Uremia Cause Vascular Dysfunction , 2011, Kidney and Blood Pressure Research.

[23]  G. Remuzzi,et al.  Treatment of Bleeding in Dialysis Patients , 2009, Seminars in dialysis.

[24]  J. Coresh,et al.  Prevalence of chronic kidney disease in the United States. , 2007, JAMA.

[25]  D. Malhotra,et al.  HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Platelet Dysfunction and End‐Stage Renal Disease , 2006 .

[26]  M. Cirillo,et al.  In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. , 2005, Kidney international.

[27]  G. Remuzzi,et al.  Platelet dysfunction in renal failure. , 2004, Seminars in thrombosis and hemostasis.

[28]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[29]  B. Psaty,et al.  Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons With Renal Insufficiency , 2003, Circulation.

[30]  G. Remuzzi,et al.  Uremic bleeding: closing the circle after 30 years of controversies? , 1999, Blood.

[31]  E. Pivalizza,et al.  Perioperative hypercoagulability in uremic patients: a viscoelastic study. , 1997, Journal of clinical anesthesia.

[32]  G. Remuzzi,et al.  Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. , 1993, Kidney international.

[33]  N. Perico,et al.  Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. , 1990, The Journal of clinical investigation.

[34]  J. Sixma,et al.  High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. , 1990, Blood.

[35]  F. Stockenhuber,et al.  Evidence for an Increased Generation of Prostacyclin in the Microvasculature and an Impairment of the Platelet α-Granule Release in Chronic Renal Failure , 1988, Thrombosis and Haemostasis.

[36]  L. Mockros,et al.  Thrombelastography of blood from subjects with chronic renal failure. , 1987, Thrombosis research.

[37]  J. Lv,et al.  Prevalence and Disease Burden of Chronic Kidney Disease. , 2019, Advances in experimental medicine and biology.

[38]  M. Carr,et al.  The effect of uremia on platelet contractile force, clot elastic modulus and bleeding time in hemodialysis patients. , 2007, Thrombosis research.

[39]  M. Crowther,et al.  Uremic bleeding: pathophysiology and clinical risk factors. , 2006, Thrombosis research.